Active, not recruitingPHASE2, PHASE3NCT06892288
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
Studying PMM2-CDG
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Glycomine, Inc.
- Principal Investigator
- Chief Medical OfficerGlycomine, Inc.
- Intervention
- GLM101 (Part A, Double-blind)(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2025 – 2027
Study locations (15)
- University of Minnesota, Minneapolis, Minnesota, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- UZ Leuven, Campus Gasthuisberg, Leuven, Belgium
- Vseobecna fakultni nemocnice v Praze, Prague, Czechia
- AP-HP Hopital Necker-Enfants Malades, Paris, France
- Universitaetsklinikum Muenster, Münster, Germany
- Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco, Catania, Italy
- Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- Instytut Matki i Dziecka, Warsaw, Poland
- Unidade Local de Saúde de Santo António, Porto, Portugal
- Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06892288 on ClinicalTrials.govOther trials for PMM2-CDG
Additional recruiting or active studies for the same condition.